

Fiscal Year 2009 Annual Review of Brovana™ (arformoterol tartrate)

The prior authorization of Brovana™ inhalation solution was implemented in November 2007 with the following criteria:


Approval Criteria:

- Member must be age 18 or older
- Diagnosis of COPD, chronic bronchitis, or emphysema
- Prior trial with Advair®, Serevent®, or Foradil® within the past 45 days
- Clinical exception for members who are unable to effectively use hand-actuated devices or are stable on nebulized therapy.
- Quantity limit of 120 ml for a 30 day supply also applies.

Utilization Trend and Details

Fiscal Year	Members	Claims	Cost	Cost/Claim	Perdiem	Units	Days
2008	15	31	\$7,347.38	\$237.01	\$8.59	3,000	855
2009	8	14	\$4,113.82	\$293.84	\$9.79	1,440	420
Percent Change	-46.70%	-54.80%	-44.00%	24.00%	14.00%	-52.00%	-50.90%
Change	-7	-17	-\$3,233.56	\$56.83	\$1.20	-1,560	-435

Demographics of Members Utilizing Brovana™



Prior Authorization of Brovana™

Approved	10
Denied	13
Incomplete	11
Total	34

Prescribers of Brovana™

Specialty	Claims	Cost
Pulmonary Disease Specialist	7	\$2,057.91
Family Practitioner	3	\$872.25
Nurse Practitioner (Other)	3	\$854.68
DDSD-NFM	1	\$328.98

Recommendations

The College of Pharmacy recommends no changes at this time.